Eli Lilly to sign $2bn deal for AI drug development with Hong Kong biotech
Global pharmaceutical companies are aggressively searching for new medicines in China
Related reading
Investors bet on Chinese companies powering global AI build-out
Companies such as battery maker CATL earn big margins on export sales despite US tariffs
400% gains for AI stocks help drive Hong Kong IPOs to 5-year high
Deal backlogs and stricter quality controls are pushing some tech firms back to mainland Chinese listings
Why investors are chasing US biotechs with Chinese characteristics
Drugs developed in Asian nation are increasingly being used to seed US start-ups
Eli Lilly becomes first pharma group to join $1tn club
Shares have soared more than 40% this year over strong demand for weight-loss and diabetes drugs
Eli Lilly pushes for NHS drug price increases in return for its UK investment
US pharmaceutical group ‘optimistic’ about reaching deal with British government
How AI can recode the difficult process of drug discovery
Research organisations are banking on technology to help improve the odds of approval